1-4 of 4
Thomas Beyer
Close
Sort by
Journal Articles

Recombinant Dimeric IgA Antibodies as Tumor-Specific Agents.

Michael Dechant, MD, Stefan Lohse, PhD, Stefanie Derer, PhD, Thomas Beyer, PhD, Katja Klausz, PhD, Matthias Peipp, PhD, Jeanette H. W. Leusen, PhD, Jan G. J. van de Winkel, PhD, Thomas Valerius, MD
Journal: Blood
Blood (2010) 116 (21): 1488.
https://doi.org/10.1182/blood.V116.21.1488.1488
Published: 2010
Journal Articles

Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells

Matthias Peipp, Jeroen J. Lammerts van Bueren, Tanja Schneider-Merck, Wim W. K. Bleeker, Michael Dechant, Thomas Beyer, Roland Repp, Patrick H. C. van Berkel, Tom Vink, Jan G. J. van de Winkel, Paul W. H. I. Parren, Thomas Valerius
Journal: Blood
Blood (2008) 112 (6): 2390–2399.
https://doi.org/10.1182/blood-2008-03-144600
Published: 2008
Includes: Supplemental data
Journal Articles

Recombinant Chimeric IgA1 and IgA2 Antibodies for Tumor Immunotherapy.

Michael Dechant, MD, Thomas Beyer, PhD, Stefan Lohse, Tanja Schneider-Merck, PhD, Wencke Weisner, Sven Berger, PhD, Matthias Peipp, PhD, Jan G.J. van de Winkel, PhD, Thomas Valerius, MD
Journal: Blood
Blood (2007) 110 (11): 4892.
https://doi.org/10.1182/blood.V110.11.4892.4892
Published: 2007
Journal Articles

Fully Human CD38 Antibodies Efficiently Trigger ADCC of Multiple Myeloma Cell Lines and Primary Tumor Cells.

Matthias Peipp, PhD, Michel de Weers, PhD, Thomas Beyer, PhD, Roland Repp, MD, Paul Parren, PhD, Thomas Valerius, MD, Jan G.J. van de Winkel, PhD
Journal: Blood
Blood (2005) 106 (11): 3377.
https://doi.org/10.1182/blood.V106.11.3377.3377
Published: 2005